Registry of Fabry Disease - A Multicenter Observational Study
| Status: | Completed |
|---|---|
| Conditions: | Hematology, Metabolic |
| Therapuetic Areas: | Hematology, Pharmacology / Toxicology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 4/21/2016 |
| Start Date: | February 2003 |
| End Date: | March 2008 |
Registry of Fabry Disease: A Multicenter, Longitudinal Observational Study
The purpose of this study is to compile a registry of patients with Fabry disease, an
inherited metabolic disorder. In this disease, an enzyme called a-galactosidase A, which
normally breaks down a lipid (fatty substance) called globotriaosylceramide (Gb3), is
missing or does not function properly. As a result, Gb3 accumulates, causing problems with
the kidneys, heart, nerves, and blood vessels. It is not known exactly how lipid
accumulation causes these problems, but in another lipid storage disease called Gaucher
disease the illness can be reversed if the accumulated lipid is removed by repeated
intravenous (into a vein) infusions of the deficient enzyme.
The Fabry disease registry is a voluntary and anonymous list of patients that includes
information about their health and allows doctors to follow changes in their symptoms and
test results over time. It also allows doctors to compare symptoms between patients who are
receiving certain therapies with those who are not receiving therapy. The goals of the
registry are to:
- Better understand the natural history of Fabry disease, including disease variations
within and between affected families;
- Provide a basis for developing guidelines for disease management;
- Evaluate how treatment affects the course of disease;
- Provide high-quality data and analyses that will help to continuously develop better
treatments.
Patients of all ages with biochemical or genetic evidence of Fabry disease (i.e.,
individuals who have a deficiency of the enzyme a-galactosidase A or a mutation in the gene
that encodes this enzyme, or both) are eligible for this study. This worldwide study will
include 100 patients participating in Fabry disease studies at the NIH. These patients will
come to the NIH Clinical Center only as required for participation their Fabry disease
study. No additional procedures will be required for the current registry study.
NIH patients will take part in the registry study for their lifetime, or as long as they are
being followed at the NIH for their Fabry disease. At their regularly scheduled NIH clinic
visits, participants will have routine medical procedures and examinations deemed necessary
by the doctor. The results of blood and urine tests taken at these visits will be entered
into the registry database. Blood tests will include information on genotype (determination
of which gene mutation is responsible for the disease), a-galactosidase A levels, Gb3
levels, and creatinine. Urine tests results will include creatinine clearance (a measure of
kidney function) and protein evaluation.
inherited metabolic disorder. In this disease, an enzyme called a-galactosidase A, which
normally breaks down a lipid (fatty substance) called globotriaosylceramide (Gb3), is
missing or does not function properly. As a result, Gb3 accumulates, causing problems with
the kidneys, heart, nerves, and blood vessels. It is not known exactly how lipid
accumulation causes these problems, but in another lipid storage disease called Gaucher
disease the illness can be reversed if the accumulated lipid is removed by repeated
intravenous (into a vein) infusions of the deficient enzyme.
The Fabry disease registry is a voluntary and anonymous list of patients that includes
information about their health and allows doctors to follow changes in their symptoms and
test results over time. It also allows doctors to compare symptoms between patients who are
receiving certain therapies with those who are not receiving therapy. The goals of the
registry are to:
- Better understand the natural history of Fabry disease, including disease variations
within and between affected families;
- Provide a basis for developing guidelines for disease management;
- Evaluate how treatment affects the course of disease;
- Provide high-quality data and analyses that will help to continuously develop better
treatments.
Patients of all ages with biochemical or genetic evidence of Fabry disease (i.e.,
individuals who have a deficiency of the enzyme a-galactosidase A or a mutation in the gene
that encodes this enzyme, or both) are eligible for this study. This worldwide study will
include 100 patients participating in Fabry disease studies at the NIH. These patients will
come to the NIH Clinical Center only as required for participation their Fabry disease
study. No additional procedures will be required for the current registry study.
NIH patients will take part in the registry study for their lifetime, or as long as they are
being followed at the NIH for their Fabry disease. At their regularly scheduled NIH clinic
visits, participants will have routine medical procedures and examinations deemed necessary
by the doctor. The results of blood and urine tests taken at these visits will be entered
into the registry database. Blood tests will include information on genotype (determination
of which gene mutation is responsible for the disease), a-galactosidase A levels, Gb3
levels, and creatinine. Urine tests results will include creatinine clearance (a measure of
kidney function) and protein evaluation.
PROTOCOL TITLE: Registry of Fabry Disease: A Multicenter, Longitudinal Observational Study
PROTOCOL IDENTIFIER: FOS (Fabry Outcome Survey)
PHASE OF DEVELOPMENT: Post Marketing Outcome Survey (Outcome Survey)
SURVEY OBJECTIVES/ENDPOINTS:
The primary objectives of this outcome survey are to:
- enhance the understanding of the natural history of Fabry disease, including the intra-
and inter-familial variations
- provide a basis for the development of management guidelines for Fabry disease
- evaluate the impact of therapeutic intervention on the clinical course of Fabry disease
- generate data and analyses to enable the continuous improvement of Fabry disease
treatment
- collect long term safety and efficacy data on patients treated with Replagal enzyme
replacement therapy
INCLUSION CRITERIA:
This registry/outcome survey is open for all patients of all ages, male and female, with a
confirmed diagnosis of Fabry disease.
EXCLUSION CRITERIA:
- Patients who are unwilling to give informed consent.
- Patients who are receiving enzyme replacement therapy other than Replagal for Fabry
Disease
- Patients currently enrolled in an ongoing blinded clinical trial in which the product
is considered investigational.
NUMBER OF SUBJECTS PLANNED AND DURATION OF SUBJECT PARTICIPATION:
There is no predetermined number of patients that must be enrolled into the outcome survey.
Patients who have been diagnosed (biochemically or genetically) with Fabry disease that
consent to participate will be followed for an undetermined amount of time (i.e., until the
sponsor closes the outcome survey or the patient withdraws consent).
TREATMENTS ADMINISTERED AND TREATMENT SCHEDULE:
Patients consenting to participate in the outcome survey will either be untreated or treated
with Replagal ERT. It is recommended that patients be followed at increments determined to
be necessary by the treating physician. It is also recommended that data on all patients be
entered into the outcome survey on a bi-annual basis (every six (6) months).
Patients will not be supplied with Replagal at no charge as a result of participating in the
Fabry Outcome Survey (FOS). Patients will receive Replagal through their participation in
ongoing open label clinical trials or compassionate programs. Additionally, patients may
receive commercially available product.
SURVEY ASSESSMENT SCHEDULE:
It is recommended that patients be followed at clinically relevant intervals determined by
their treating physician. Data collected is to be entered into the FOS database as soon as
possible after physician assessments.
SURVEY METHODOLOGY:
Observational data will be recorded in the FOS database based on routine clinical
evaluations performed by the treating physician.
STATISTICAL METHODOLOGY:
The statistical analysis of FOS data will be performed by a bio-statistician designated by
Shire HGT and in accordance with documented company guidelines and standard operating
procedures.
PROTOCOL IDENTIFIER: FOS (Fabry Outcome Survey)
PHASE OF DEVELOPMENT: Post Marketing Outcome Survey (Outcome Survey)
SURVEY OBJECTIVES/ENDPOINTS:
The primary objectives of this outcome survey are to:
- enhance the understanding of the natural history of Fabry disease, including the intra-
and inter-familial variations
- provide a basis for the development of management guidelines for Fabry disease
- evaluate the impact of therapeutic intervention on the clinical course of Fabry disease
- generate data and analyses to enable the continuous improvement of Fabry disease
treatment
- collect long term safety and efficacy data on patients treated with Replagal enzyme
replacement therapy
INCLUSION CRITERIA:
This registry/outcome survey is open for all patients of all ages, male and female, with a
confirmed diagnosis of Fabry disease.
EXCLUSION CRITERIA:
- Patients who are unwilling to give informed consent.
- Patients who are receiving enzyme replacement therapy other than Replagal for Fabry
Disease
- Patients currently enrolled in an ongoing blinded clinical trial in which the product
is considered investigational.
NUMBER OF SUBJECTS PLANNED AND DURATION OF SUBJECT PARTICIPATION:
There is no predetermined number of patients that must be enrolled into the outcome survey.
Patients who have been diagnosed (biochemically or genetically) with Fabry disease that
consent to participate will be followed for an undetermined amount of time (i.e., until the
sponsor closes the outcome survey or the patient withdraws consent).
TREATMENTS ADMINISTERED AND TREATMENT SCHEDULE:
Patients consenting to participate in the outcome survey will either be untreated or treated
with Replagal ERT. It is recommended that patients be followed at increments determined to
be necessary by the treating physician. It is also recommended that data on all patients be
entered into the outcome survey on a bi-annual basis (every six (6) months).
Patients will not be supplied with Replagal at no charge as a result of participating in the
Fabry Outcome Survey (FOS). Patients will receive Replagal through their participation in
ongoing open label clinical trials or compassionate programs. Additionally, patients may
receive commercially available product.
SURVEY ASSESSMENT SCHEDULE:
It is recommended that patients be followed at clinically relevant intervals determined by
their treating physician. Data collected is to be entered into the FOS database as soon as
possible after physician assessments.
SURVEY METHODOLOGY:
Observational data will be recorded in the FOS database based on routine clinical
evaluations performed by the treating physician.
STATISTICAL METHODOLOGY:
The statistical analysis of FOS data will be performed by a bio-statistician designated by
Shire HGT and in accordance with documented company guidelines and standard operating
procedures.
- INCLUSION CRITERIA:
This registry is open for all patients of all ages, male and female, with a confirmed
diagnosis of Fabry disease.
EXCLUSION CRITERIA:
Patients who are unwilling to give informed consent.
Patients who are receiving enzyme replacement therapy other than Replagal for Fabry
Disease.
Patients currently enrolled in an ongoing blinded clinical trial in which the product is
considered investigational.
We found this trial at
2
sites
9000 Rockville Pike
Bethesda, Maryland 20892
Bethesda, Maryland 20892
Click here to add this to my saved trials
Click here to add this to my saved trials